CEL-SCI Corporation Form 8-K Summary
Business Context and Reporting Period
CEL-SCI Corporation (CEL-SCI), a Colorado corporation, filed this Current Report on Form 8-K on March 17, 2025. The filing details the entry into a Material Definitive Agreement regarding a private placement offering of equity securities.
Key Financial Metrics and Transaction Details
- Transaction Type: Sale of common stock and pre-funded warrants.
- Common Stock Issued: 4,012,500 shares at $0.16 per share.
- Pre-Funded Warrants Issued: Warrants to purchase up to 11,987,500 shares at $0.1599 per warrant (exercise price $0.0001).
- Gross Proceeds: $2,560,000 (exclusive of warrant exercise price and before fees).
- Placement Agent Fees: 7.0% of gross proceeds plus up to $80,000 in expense reimbursement.
- Use of Proceeds: Funding continued development of Multikine, general corporate purposes, and working capital.
- Liquidity Impact: The filing does not provide current cash balances, debt levels, or operating margins; it focuses solely on the capital raise.
Material Changes and Agreements
The primary material change is the dilution of existing shareholders due to the issuance of approximately 16 million new shares (including warrant coverage). The company entered into a 30-day lock-up period (from March 17, 2025) restricting the issuance of additional equity. Directors and officers are subject to a 45-day lock-up agreement.
Guidance, Outlook, and Risks
Management intends to utilize the net proceeds to advance the development of Multikine. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from projections. Specific risk factors are referenced in the company's prospectus supplement and 2024 Form 10-K but are not detailed in this 8-K text.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7% placement fee and the $80,000 expense cap.
- Confirm the exact number of shares outstanding post-closing to assess dilution impact.
- Review the March 17, 2025, prospectus supplement for specific risk factors related to the Multikine development program.
- Check the company's most recent 10-K or 10-Q for current cash runway and debt obligations to contextualize the $2.56 million raise.